[1] 于乐成, 陈成伟. 药物性肝损伤的发生机制:当前认识和未来需求. 临床肝胆病杂志, 2021,37(11): 2515-2524. [2] Clinton JW,Kiparizoska S, Aggarwal S, et al. Drug-induced liver injury: Highlights and controversies in the recent literature. Drug Saf, 2021,44(11):1125-1149. [3] 中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版). 中华肝脏病杂志, 2023,31(4): 355-384. [4] 杨雪, 涂荣芳, 杨晋辉. 498 例药物性肝损伤患者的临床特点及其预后分析. 中华肝脏病杂志,2022,30(7):735-740. [5] Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: A french population-based study. Hepatology, 2002,36(2):451-455. [6] Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland. Gastroenterology, 2013,144(7):1419-25, 1425,e1-3; quiz e19-20. [7] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland china. Gastroenterology, 2019,156(8):2230-2241,e11. [8] Lucena MI, Kaplowitz N, Hallal H, et al. Recurrent drug-induced liver injury with different drugs in the Spanish registry: The dilemma of the relationship to autoimmune hepatitis. J Hepatol, 2011,55(4):820-827. [9] Stephens C, Robles-Diaz M, Medina-Caliz I, et al. Comprehensive analysis and insights gained from long-term experience of the spanish DILI registry. J Hepatol, 2021,75(1):86-97. [10] de Boer YS,Kosinski AS, Urban TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol, 2017,15(1):103-112,e2. [11] Licata A, Maida M,Cabibi D, et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. Dig Liver Dis, 2014,46(12):1116-1120. [12] 李变利, 彭颖, 杨柳, 等. 药物诱导性自身免疫性肝炎临床特征分析. 中国临床药理学杂志, 2021,37(17): 2258-2261. [13] George N, Chen M, Yuen N, et al. Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury.Regul Toxicol Pharmacol, 2018,94:101-107. [14] Ortona E, Pierdominici M, Maselli A, et al. Sex-based differences in autoimmune diseases. Ann Ist Super Sanita, 2016,52(2):205-212. [15] 符馨尹, 林小茹, 郑秀芬, 等. 药物诱导性自身免疫性肝炎与药物性肝损伤和自身免疫性肝炎患者临床特征比较研究. 实用肝脏病杂志, 2023,26(4):512-515. [16] Hisamochi A, Kage M, Ide T, et al. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. J Gastroenterol, 2016,51(6):597-607. [17] Lee HA, Jung JY, Lee YS, et al. Direct bilirubin is more valuable than total bilirubin for predicting prognosis in patients with liver cirrhosis. Gut Liver, 2021,15(4):599-605. [18] Kumagai K, Mawatari S, Moriuchi A, et al. Early-phase prothrombin time-international normalized ratio in acute liver injury indicates the timing of therapeutic intervention and predicts prognostic improvement. Hepatol Res, 2023;53(2):160-171. |